RESUMEN
Objective@#To evaluate the clinical efficacy of invisible orthodontic appliances without brackets for the distal movement of maxillary molars to improve the ability of orthodontists to predict treatment outcomes.@*Methods@#Web of Science, Cochrane Library, Embase, PubMed, Wanfang Database, CNKI Database, and VIP Database were searched for studies investigating the efficacy of invisible orthodontic appliances for distal movement of maxillary molars in adult patients and published from database inception to August 1, 2023. A total of three researchers screened the studies and evaluated their quality and conducted a meta-analysis of those that met quality standards.@*Results@#This study included 13 pre- and postcontrol trials with a total sample size of 281 patients. The meta-analysis revealed no significant differences in the sagittal or vertical parameters of the jawbone after treatment when compared with those before treatment (P>0.05). The displacement of the first molar was MD=-2.34, 95% CI (-2.83, -1.85); the displacement was MD=-0.95, 95% CI (-1.34, -0.56); and the inclination was MD=-2.51, 95% CI (-3.56, -1.46). There was a statistically significant difference in the change in sagittal, vertical, and axial tilt of the first molar before and after treatment. After treatment, the average adduction distance of the incisors was MD=-0.82, 95% CI (-1.54, -0.09), and the decrease in lip inclination was MD=-1.61, 95% CI (-2.86, -0.36); these values were significantly different from those before treatment (P<0.05).@*Conclusion@#Invisible orthodontic appliances can effectively move the upper molars in a distal direction and control the vertical position of the molars. When the molars move further away, there is some degree of compression and distal tilt movement, which is beneficial for patients with high angles. The sagittal movement of incisors is beneficial for improving the patient's profile.
RESUMEN
Objective To study the activities of different gene promoters in colon cancer stem cells and to search for effective promoter for targeted therapy of colon cancer stem cells. Methods CD133+CD44+ cells were sorted from cell line HCT116 by flow cytometry. Nanog, Mud and Survivin gene promoters were amplified by PCR and were separately cloned into pGL3-basic plasmid. pGL3-basic-promoter plasmid or pGL3-basic-control plasmid together with plasmid pRL-sv40 were co-transfected into colon cancer cell lines (HCT116,SW620, and HT29), CD133+CD44+ HCT116 cells, and normal human liver cell line QSG7701. And then promoter activitywas examined by dual-luciferase assays. Results The constructed pGL3-basic-Nanog, pGL3-basic-Md1 and pGL3-basic-Survivin were confirmed correct by sequencing. We found that 42. 2% of HCT116 cells were CD133+CD44+ cells. Dual-luciferase activity detection showed that Mud and Survivin promoters had strong activities in both colon cancer cells and CD133+ CD44+ HCT116 cells, and they had low activities in normal cells QSG7701. Conclusion Survivin and Mud promoters may serve as effective candidate for targeted treatment of colon cancer stem cells.
RESUMEN
Objective To study the activities of different gene promoters in colon cancer stem cells and to search for effective promoter for targeted therapy of colon cancer stem cells. Methods CD133+CD44+ cells were sorted from cell line HCT116 by flow cytometry. Nanog, Mud and Survivin gene promoters were amplified by PCR and were separately cloned into pGL3-basic plasmid. pGL3-basic-promoter plasmid or pGL3-basic-control plasmid together with plasmid pRL-sv40 were co-transfected into colon cancer cell lines (HCT116,SW620, and HT29), CD133+CD44+ HCT116 cells, and normal human liver cell line QSG7701. And then promoter activitywas examined by dual-luciferase assays. Results The constructed pGL3-basic-Nanog, pGL3-basic-Md1 and pGL3-basic-Survivin were confirmed correct by sequencing. We found that 42. 2% of HCT116 cells were CD133+CD44+ cells. Dual-luciferase activity detection showed that Mud and Survivin promoters had strong activities in both colon cancer cells and CD133+ CD44+ HCT116 cells, and they had low activities in normal cells QSG7701. Conclusion Survivin and Mud promoters may serve as effective candidate for targeted treatment of colon cancer stem cells.